Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?"

de Souza, Ana Luísa Caires and Acurcio, Francisco de Assis and Guerra Júnior, Augusto Afonso and do Nascimento, Renata Cristina Rezende Macedo and Godman, Brian and Diniz, Leonardo Maurício (2014) Authors’ reply to Dr. Malerbi: "Insulin glargine in a Brazilian state: should the government disinvest?". Applied Health Economics and Health Policy, 12 (5). pp. 561-563. ISSN 1179-1896

[thumbnail of Godman-etal-AHEHP-2014-Authors-reply-to-Dr-Malerbi]
Preview
PDF (Godman-etal-AHEHP-2014-Authors-reply-to-Dr-Malerbi)
Godman_etal_AHEHP_2014_Authors_reply_to_Dr_Malerbi.pdf
Accepted Author Manuscript

Download (301kB)| Preview

    Abstract

    Dear Editor, We thank Dr. Malerbi for his comments regarding the systematic review [1]: “Insulin Glargine in the Brazilian State: Should the Government Disinvest? An Assessment Based on a Systematic Review” [2]. In particular, we thank Dr. Malerbi for pointing out the recently published ORIGIN study [3] clarifying the situation regarding insulin glargine and its neutral effects on the development of cancer following the previous observations of Hemkens et al. and Jonasson et al. [4, 5]. This will be welcomed by patients. However, we were concerned by his comments that we “seem to have prepared their review with the primary motivation of justifying—both on administrative and juridical grounds—the denial from the government to dispense insulin analogues to those diabetic patients who need them”.